[go: up one dir, main page]

MX2022003401A - Compuesto de piridona fusionada y metodo de preparacion del mismo y uso del mismo. - Google Patents

Compuesto de piridona fusionada y metodo de preparacion del mismo y uso del mismo.

Info

Publication number
MX2022003401A
MX2022003401A MX2022003401A MX2022003401A MX2022003401A MX 2022003401 A MX2022003401 A MX 2022003401A MX 2022003401 A MX2022003401 A MX 2022003401A MX 2022003401 A MX2022003401 A MX 2022003401A MX 2022003401 A MX2022003401 A MX 2022003401A
Authority
MX
Mexico
Prior art keywords
preparation
method therefor
compound
pyridone compound
fused
Prior art date
Application number
MX2022003401A
Other languages
English (en)
Inventor
Haibing Guo
Yang Liu
Jianbiao Peng
Jun Fan
Shuchun Guo
Fang Bao
Original Assignee
Shanghai Jemincare Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jemincare Pharmaceuticals Co Ltd filed Critical Shanghai Jemincare Pharmaceuticals Co Ltd
Publication of MX2022003401A publication Critical patent/MX2022003401A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

En la presente invención se describe un compuesto de piridona fusionada, y un método de preparación para este y un uso de este. Específicamente, la presente invención describe un compuesto de la fórmula (I-B), un isómero óptico del mismo y una sal farmacéuticamente aceptable del mismo, y el uso del compuesto como un inhibidor de KRAS. (ver fórmula).
MX2022003401A 2019-09-20 2020-09-21 Compuesto de piridona fusionada y metodo de preparacion del mismo y uso del mismo. MX2022003401A (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
CN201910892032 2019-09-20
CN201911129688 2019-11-18
CN201911157939 2019-11-22
CN202010054188 2020-01-17
CN202010102546 2020-02-19
CN202010230303 2020-03-27
CN202010306926 2020-04-17
CN202010367694 2020-04-30
CN202010967317 2020-09-15
PCT/CN2020/116510 WO2021052499A1 (zh) 2019-09-20 2020-09-21 稠合吡啶酮类化合物及其制备方法和应用

Publications (1)

Publication Number Publication Date
MX2022003401A true MX2022003401A (es) 2022-07-13

Family

ID=74883935

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003401A MX2022003401A (es) 2019-09-20 2020-09-21 Compuesto de piridona fusionada y metodo de preparacion del mismo y uso del mismo.

Country Status (15)

Country Link
US (1) US20220389029A1 (es)
EP (1) EP4043464A4 (es)
JP (1) JP7642619B2 (es)
KR (1) KR20220086573A (es)
CN (5) CN118619971A (es)
AU (1) AU2020350745A1 (es)
BR (1) BR112022005193A2 (es)
CA (1) CA3155066A1 (es)
CL (1) CL2022000666A1 (es)
CO (1) CO2022004686A2 (es)
IL (1) IL291467A (es)
MX (1) MX2022003401A (es)
PH (1) PH12022550681A1 (es)
TW (1) TWI761961B (es)
WO (1) WO2021052499A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
KR102871791B1 (ko) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
WO2020055760A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CA3111980A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
SI3849537T1 (sl) 2018-09-10 2025-03-31 Mirati Therapeutics, Inc. Kombinirane terapije
EP3871673B1 (en) 2018-10-26 2024-01-03 Taiho Pharmaceutical Co., Ltd. Novel indazole compound or salt thereof
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
JP7592601B2 (ja) 2019-01-10 2024-12-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
SG11202111327XA (en) 2019-05-13 2021-11-29 Relay Therapeutics Inc Fgfr inhibitors and methods of use thereof
AU2020337938B2 (en) 2019-08-29 2025-09-25 Array Biopharma Inc. KRas G12D inhibitors
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
JP2022548791A (ja) 2019-09-24 2022-11-21 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
MX2022005053A (es) 2019-10-28 2022-05-18 Merck Sharp & Dohme Llc Inhibidores de peque?as moleculas de mutante g12c de kras.
KR102894761B1 (ko) 2019-10-30 2025-12-02 젠플리트 테라퓨틱스 (상하이) 아이엔씨. 치환된 헤테로환형 융합된 환형 화합물, 이의 제조 방법 및 이의 약학적 용도
KR20220109408A (ko) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. Ras 억제제
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
AU2020405170A1 (en) 2019-12-20 2022-06-30 Mirati Therapeutics, Inc. SOS1 inhibitors
JP7461499B2 (ja) * 2020-04-03 2024-04-03 メッドシャイン ディスカバリー インコーポレイテッド オクタヒドロピラジノジアザナフチリジンジオン化合物
CN116406363B (zh) * 2020-08-21 2025-06-20 浙江海正药业股份有限公司 四环类衍生物、其制备方法及其医药上的用途
AU2021340716A1 (en) 2020-09-11 2023-03-30 Mirati Therapeutics, Inc. Crystalline forms of a KRas G12C inhibitor
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
TW202233625A (zh) 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
US12398154B2 (en) 2020-12-15 2025-08-26 Mirati Therapeutics, Inc. Azaquinazoline pan-KRas inhibitors
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022143995A1 (zh) * 2020-12-31 2022-07-07 正大天晴药业集团股份有限公司 四环类化合物及其医药用途
TW202246267A (zh) * 2021-03-25 2022-12-01 大陸商上海濟煜醫藥科技有限公司 稠合吡啶酮類化合物鹽型、晶型及其應用
CN115124533A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 四环类衍生物、其制备方法和其医药上的用途
CN116848111A (zh) * 2021-03-26 2023-10-03 浙江海正药业股份有限公司 一种kras抑制剂关键中间体及其制备方法
CN116113632B (zh) * 2021-03-30 2025-08-29 浙江海正药业股份有限公司 杂环类衍生物、其制备方法及其医药上的用途
WO2022223037A1 (zh) * 2021-04-22 2022-10-27 劲方医药科技(上海)有限公司 Kras抑制剂的盐或多晶型物
JP2024525993A (ja) * 2021-07-23 2024-07-12 スゾウ、ザンロン、ファーマ、リミテッド Ｋｒａｓ ｇ１２ｄ阻害剤およびその使用
WO2023030517A1 (en) * 2021-09-06 2023-03-09 Suzhou Zanrong Pharma Limited Kras g12c inhibitors and uses thereof
EP4455147A4 (en) * 2021-12-24 2026-01-07 Genfleet Therapeutics Shanghai Inc KRAS INHIBITOR POLYMORPH, ITS PREPARATION PROCESS AND ITS USE
CN116327956B (zh) * 2022-04-01 2025-11-28 劲方医药科技(上海)股份有限公司 药物组合物、其用途及癌症的治疗方法
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
TW202506674A (zh) * 2023-07-19 2025-02-16 大陸商上海濟煜醫藥科技有限公司 Kras抑制劑的製備方法、其中間體和其中間體的製備方法
WO2025036442A1 (zh) * 2023-08-15 2025-02-20 劲方医药科技(上海)股份有限公司 吡嗪并萘啶二酮类化合物的制备方法及其中间体
TW202529768A (zh) 2023-09-29 2025-08-01 大陸商德昇濟醫藥（無錫）有限公司 癌症治療的療法
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160076519A (ko) * 2013-10-10 2016-06-30 아락세스 파마 엘엘씨 Kras g12c 억제제
JO3556B1 (ar) * 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
BR112017021869A2 (pt) * 2015-04-10 2018-12-11 Araxes Pharma Llc compostos quinazolina substituídos e métodos de uso dos mesmos
US10428064B2 (en) * 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
KR102161364B1 (ko) * 2015-09-14 2020-09-29 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
MX2018005967A (es) 2015-11-16 2018-08-29 Araxes Pharma Llc Compuestos de quinazolina 2-sustituida que comprenden un grupo heterociclico sustituido y metodos de uso de los mismos.
WO2017100546A1 (en) * 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US20200010479A1 (en) * 2017-02-03 2020-01-09 The University Of North Carolina At Chapel Hill Inhibitors of microbial beta-glucuronidase enzymes and uses thereof
WO2018206539A1 (en) * 2017-05-11 2018-11-15 Astrazeneca Ab Heteroaryl compounds that inhibit g12c mutant ras proteins
JOP20190272A1 (ar) * 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
TW201938561A (zh) * 2017-12-08 2019-10-01 瑞典商阿斯特捷利康公司 化學化合物
CN112442030B (zh) * 2018-01-19 2022-09-27 南京明德新药研发有限公司 作为krasg12c突变蛋白抑制剂的吡啶酮并嘧啶类衍生物
EP3788038B1 (en) * 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
US20220064141A1 (en) * 2019-01-29 2022-03-03 Brightgene Bio-Medical Technology Co., Ltd. Benzopyridone heterocyclic compound and use thereof
WO2020239123A1 (zh) * 2019-05-31 2020-12-03 上海翰森生物医药科技有限公司 芳香杂环类衍生物调节剂、其制备方法和应用
CN112300194B (zh) * 2019-07-30 2022-01-14 上海凌达生物医药有限公司 一类稠环吡啶酮类化合物、制备方法和用途
KR102894761B1 (ko) * 2019-10-30 2025-12-02 젠플리트 테라퓨틱스 (상하이) 아이엔씨. 치환된 헤테로환형 융합된 환형 화합물, 이의 제조 방법 및 이의 약학적 용도

Also Published As

Publication number Publication date
IL291467A (en) 2022-05-01
TW202126654A (zh) 2021-07-16
PH12022550681A1 (en) 2023-04-24
CN116947885B (zh) 2026-01-23
US20220389029A1 (en) 2022-12-08
BR112022005193A2 (pt) 2022-08-16
CA3155066A1 (en) 2021-03-25
AU2020350745A1 (en) 2022-04-07
EP4043464A4 (en) 2023-10-04
WO2021052499A1 (zh) 2021-03-25
KR20220086573A (ko) 2022-06-23
CL2022000666A1 (es) 2022-10-14
CN116947885A (zh) 2023-10-27
CN114728968A (zh) 2022-07-08
CN119462689A (zh) 2025-02-18
TWI761961B (zh) 2022-04-21
EP4043464A1 (en) 2022-08-17
JP7642619B2 (ja) 2025-03-10
JP2022549171A (ja) 2022-11-24
CN119591618A (zh) 2025-03-11
CO2022004686A2 (es) 2022-07-08
CN114728968B (zh) 2024-11-15
CN118619971A (zh) 2024-09-10

Similar Documents

Publication Publication Date Title
PH12022550681A1 (en) Fused pyridone compound, and preparation method therefor and use thereof
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
ZA202208783B (en) Kras mutant protein inhibitors
ZA202206923B (en) New methylquinazolinone derivatives
CR20220354A (es) Inhibidores de egfr
AU2018271990A1 (en) Covalent inhibitors of KRAS
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
MX2021007247A (es) Derivados de rapamicina.
PH12022551241A1 (en) Egfr inhibitors
PH12021550883A1 (en) Crystalline salts of a plasma kallikrein inhibitor
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX394860B (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
AU2017257755A1 (en) Benzoylglycine derivatives and methods of making and using same
SG11201810725WA (en) Novel β-lactamase inhibitors
SG11201907945YA (en) Azetidine derivative
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
AU2019296118A8 (en) Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
PH12022550529A1 (en) Magl inhibitor, preparation method and use thereof
EP4649947A3 (en) Methods for treating against viruses
ZA201904033B (en) Pharmaceutical compounds
MY208423A (en) Composition of aminopyran derivative
HK40061236A (zh) 特定vmat2抑制剂的施用方法